Search | Clinical Trials Finder

Conditions: Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer
Interventions: galinpepimut-S, pembrolizumab, Montanide, GM-CSF; Biological · Other
Lead sponsor: Sellas Life Sciences Group; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 12
States / cities: Santa Rosa, California • Whittier, California • Miami, Florida + 9 more

Conditions: Newly Diagnosed Glioblastoma
Interventions: SurVaxM; Biological
Lead sponsor: MimiVax, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 11
States / cities: San Francisco, California • Miami, Florida • Louisville, Kentucky + 7 more

Conditions: Triple-Negative Breast Cancer (TNBC)
Interventions: BreakVax, Ipilimumab 2.5 mg, Pembrolizumab, Standard-of-care chemotherapy, Losartan and aspirin; Drug
Lead sponsor: BreakBio Corp; Industry
Eligibility: 18 Years to 72 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Autoimmune Disorders
Interventions: Immucothel Alone (Part A), Immucothel+Montanide (Part A), Immucothel Alone or Immucothel+Montanide (Part B); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Extraocular Extension Melanoma, Iris Melanoma, Metastatic Intraocular Melanoma, Mucosal Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma, Stage IIC Melanoma, Stage IIIA Intraocular Melanoma, Stage IIIA Melanoma, Stage IIIB Intraocular Melanoma, Stage IIIB Melanoma, Stage IIIC Intraocular Melanoma, Stage IIIC Melanoma, Stage IV Intraocular Melanoma, Stage IV Melanoma
Interventions: gp100 antigen, tyrosinase peptide, recombinant MAGE-3.1 antigen, multi-epitope melanoma peptide vaccine, incomplete Freund's adjuvant, Montanide ISA 51 VG, agatolimod sodium, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: University of Southern California; Other
Eligibility: 16 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Adult Brain Glioblastoma, Glioblastoma Multiforme
Interventions: SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose), Bevacizumab, SL-701 + GM-CSF, Imiquimod; Drug
Lead sponsor: Stemline Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 16
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 13 more

Conditions: Patients With Non-Small Cell Lung Cancer
Interventions: OSE2101, Docetaxel, NGS HLAA2 assay; Drug · Device
Lead sponsor: OSE Immunotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 363 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 79
States / cities: Beverly Hills, California • Encino, California • Los Angeles, California + 56 more

Conditions: Digestive System Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm, Malignant Solid Neoplasm, Pancreatic Neuroendocrine Neoplasm
Interventions: Biospecimen Collection, Computed Tomography, Incomplete Freund''s Adjuvant, Magnetic Resonance Imaging, Sargramostim, SVN53-67/M57-KLH Peptide Vaccine, Temozolomide; Procedure · Biological · Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Epithelial Ovarian, Tubal or Peritoneal Cancer
Interventions: tumor peptide vaccine; Biological
Lead sponsor: Michael Morse, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Recurrent Melanoma, Stage IV Melanoma
Interventions: tyrosinase peptide, MART-1:27-35 peptide vaccine, gp100 antigen, incomplete Freund's adjuvant, sargramostim, laboratory biomarker analysis; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Melanoma
Interventions: 6MHP, Montanide ISA-51, polyICLC, Cyclophosphamide; Biological · Drug
Lead sponsor: Craig L Slingluff, Jr; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Myelodysplastic Syndromes
Interventions: PR1 leukemia peptide vaccine, incomplete Freund's adjuvant, sargramostim; Biological
Lead sponsor: The Vaccine Company; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Leukemia
Interventions: PR1 leukemia peptide vaccine, sargramostim, placebo; Biological · Other
Lead sponsor: The Vaccine Company; Industry
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 15
States / cities: Scottsdale, Arizona • Los Angeles, California • South San Francisco, California + 10 more

Conditions: Melanoma
Interventions: GM-CSF-in-adjuvant, Montanide ISA-51, GM-CSF and Montanide ISA-51, Saline; Drug · Biological
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 85 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Leukemia
Interventions: Peptide Vaccine (PR1 Peptide), Peginterferon alfa-2b, Imatinib, GM-CSF; Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Melanoma
Interventions: MDX-CTLA4 Antibody; Tyrosinase/gp100/MART-1 Peptides Melanoma Vaccine; Biological
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Melanoma
Interventions: DC Vaccine, Montanide Vaccine, Poly-ICLC; Biological
Lead sponsor: Nina Bhardwaj; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: New York, New York

Conditions: Intraocular Melanoma, Melanoma (Skin)
Interventions: gp100 antigen, incomplete Freund's adjuvant, ipilimumab; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Melanoma (Skin)
Interventions: incomplete Freund's adjuvant, melanoma helper peptide vaccine, multi-epitope melanoma peptide vaccine, sargramostim, tetanus peptide melanoma vaccine; Biological
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 65
States / cities: Palo Alto, California • Stanford, California • Lewes, Delaware + 50 more

Conditions: Neoplasms, Esophageal Neoplasms, Esophagus Neoplasm, Esophagus Cancer, Neoplasms, Esophageal, Esophageal Cancer (EsC)
Interventions: Nivolumab, Entinostat, Montanide(R) ISA-51 VG Adjuvant, H1299 Cell Lysates; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: incomplete Freund's adjuvant, sargramostim, telomerase: 540-548 peptide vaccine; Biological
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years to 120 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Melanoma (Skin)
Interventions: incomplete Freund's adjuvant, melanoma helper peptide vaccine, multi-epitope melanoma peptide vaccine, tetanus toxoid helper peptide, cyclophosphamide; Biological · Drug
Lead sponsor: Craig L Slingluff, Jr; Other
Eligibility: 18 Years to 120 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania • Houston, Texas • Charlottesville, Virginia

Conditions: Breast Cancer
Interventions: OCPM Immunotherapeutic Vaccine; Biological
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Yellow Fever, Yellow Fever Immunisation
Interventions: ISA-720, MVA Smallpox Vaccine, MVA-BN Yellow Fever Vaccine, Placebo, YF Vax 17D Strain; Drug · Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Iowa City, Iowa • St Louis, Missouri

Search by objective public record fields.

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)

Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

A Study to Determine the Immunogenicity and Oral Tolerance to Keyhole Limpet Hemocyanin (KLH)

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant With Ovarian, Tubal or Peritoneal Cancer

Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma

Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma

Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission

Evaluation of the Effects of Local Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes: MEL38

Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)

Novel Adjuvants for Peptide-Based Melanoma Vaccines

A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence

Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer

Vaccine Plus Montanide ISA-51 and Sargramostim in Treating Patients With Stage IV Breast Cancer

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Study of Cancer Peptides Vaccine Plus GM-CSF as Adjuvant Treatment for High Risk (TXN2-3M0) or Metastatic Breast Cancer With No Evidence of Disease

A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers